Genotoxicity studies on DNA-interactive telomerase inhibitors with application as anti-cancer agents
Harrington, Dean J. Cemeli, Eduardo Carder, Joanna Fearnley, Jamie Estdale, Siân E. Perry, Philip J. Jenkins, Terence C. Anderson, Diana
Harrington, Dean J.
Cemeli, Eduardo
Carder, Joanna
Fearnley, Jamie
Estdale, Siân E.
Perry, Philip J.
Jenkins, Terence C.
Anderson, Diana
Publication Date
2003-12
End of Embargo
Supervisor
Rights
Peer-Reviewed
Yes
Open Access status
closedAccess
Accepted for publication
2003-07-07
Institution
Department
Awarded
Embargo end date
Collections
Abstract
Telomerase-targeted strategies have aroused recent interest in anti-cancer chemotherapy, because DNA-binding drugs can interact with high-order tetraplex rather than double-stranded (duplex) DNA targets in tumour cells. However, the protracted cell-drug exposure times necessary for clinical application require that telomerase inhibitory efficacy must be accompanied by both low inherent cytotoxicity and the absence of mutagenicity/genotoxicity. For the first time, the genotoxicity of a number of structurally diverse DNA-interactive telomerase inhibitors is examined in the Ames test using six Salmonella typhimurium bacterial strains (TA1535, TA1537, TA1538, TA98, TA100, and TA102). DNA damage induced by each agent was also assessed using the Comet assay with human lymphocytes. The two assay procedures revealed markedly different genotoxicity profiles that are likely to reflect differences in metabolism and/or DNA repair between bacterial and mammalian cells. The mutational spectrum for a biologically active fluorenone derivative, shown to be mutagenic in the TA100 strain, was characterised using a novel and rapid assay method based upon PCR amplification of a fragment of the hisG46 allele, followed by RFLP analysis. Preliminary analysis indicates that the majority (84%) of mutations induced by this compound are C→A transversions at position 2 of the missense proline codon of the hisG46 allele. However, despite its genotoxic bacterial profile, this fluorenone agent gave a negative response in the Comet assay, and demonstrates how unwanted systemic effects (e.g., cytotoxicity and genotoxicity) can be prevented or ameliorated through suitable molecular fine-tuning of a candidate drug in targeted human tumour cells.
Version
No full-text in the repository
Citation
Harrington DJ, Cemeli E, Carder J et al (2003) Genotoxicity studies on DNA-interactive telomerase inhibitors with application as anti-cancer agents. Teratogenesis, Carcinogenesis, and Mutagenesis. 23(S2): 31-41.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article